loading page

Case Report: Successful treatment of anti-MDA5-positive to negative dermatomyositis-associated interstitial lung disease with the JAK inhibitor tofacitinib
  • +1
  • JIANG Zong,
  • Xiaoling Yao,
  • Fang Tang,
  • Wukai Ma
JIANG Zong
Guizhou University of Traditional Chinese Medicine

Corresponding Author:[email protected]

Author Profile
Xiaoling Yao
Guizhou University of Traditional Chinese Medicine
Author Profile
Fang Tang
Guizhou University of Traditional Chinese Medicine
Author Profile
Wukai Ma
Guizhou University of Traditional Chinese Medicine
Author Profile

Abstract

Anti-MDA5 antibody-positive dermatomyositis (DM) is a rare clinical autoimmune disease, and anti-MDA5-positive DM with interstitial lung disease (ILD) is the most important cause of death in DM patients. We reported the efficacy of the JAK1/3 inhibitor tofacitinib as an anti-MDT5-negative treatment option for patients with anti-MDA5-positive DM-ILD. Here we report a 51-year-old female patient with cough, sputum, shortness of breath for 5 months, rash for 3 months, and muscle pain in the extremities for 1 month. After conventional immunosuppressive therapy plus hormone therapy, the remission was slow. Methylprednisolone was successfully reduced after we administered tofacitinib and tacrolimus. After 132 weeks of follow-up, anti-MDA5 antibody turned negative, clinical symptoms were relieved, and lung Imaging tests were successfully reversed. There is currently no report of tofacitinib supplement therapy for anti-MDA5 positive to negtive DM. With this case report, tofacitinib is an option for the treatment of anti-MDA5-positive DM-ILD, which deserves attention.
02 Apr 2023Submitted to Immunity, Inflammation and Disease
05 Apr 2023Submission Checks Completed
05 Apr 2023Assigned to Editor
05 Apr 2023Review(s) Completed, Editorial Evaluation Pending
12 Apr 2023Reviewer(s) Assigned
02 May 2023Editorial Decision: Revise Major
08 May 20231st Revision Received
09 May 2023Submission Checks Completed
09 May 2023Assigned to Editor
09 May 2023Review(s) Completed, Editorial Evaluation Pending
09 May 2023Reviewer(s) Assigned
10 May 2023Editorial Decision: Revise Minor
10 May 20232nd Revision Received
12 May 2023Assigned to Editor
12 May 2023Submission Checks Completed
12 May 2023Review(s) Completed, Editorial Evaluation Pending
13 May 2023Reviewer(s) Assigned
14 May 2023Editorial Decision: Accept